We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Filter System Protects Against Catheterization Emboli

By HospiMedica International staff writers
Posted on 14 Jan 2015
A novel distal embolic protection system allows physicians to navigate challenging anatomies with confidence during minimally invasive catheterization procedures.

The Wirion filter system is a one-size embolic protection device that allows the physician to use any 0.014" guidewire throughout the entire procedure, covering vessels ranging between 3.5–6 mm in diameter. More...
At the heart of the system is proprietary deliver, lock, and deploy (DLD) technology that enables in-situ locking of cardiovascular devices onto a standard guide wire, without affecting procedure workflow. The physician can thus lock the uniform, 120 μm pore filter anywhere along the wire, providing continuous blood flow while maintaining capture efficiency and optimal side branch protection, and without compromising wire support and stability.

The mechanism is remotely activated from the proximal end, locking and deploying the stand-alone filter onto the independent guide wire, creating an in-situ embolic protection unit. Once the stent procedure is completed, the filter is removed using a retrieval catheter which employs retractable tip technology, ensuring smooth deliverability across the stented area, particularly in tortuous anatomies and open cell design stents. The Wirion filter system is a product of Allium Medical (Caesarea, Israel), and has received the European Community CE marking of approval.

“The ability to cross the lesion over the guide wire of choice and then deploy the filter in place creates a unique, natural and appealing advantage for all indications,” concluded Dierk Scheinert, MD, who led the clinical trials of the device at the University of Leipzig (Germany) Heart Center. “Clinical outcomes appear to be favorable and the role of this new device in carotid artery stenting needs to be further confirmed in a larger patient population.”

During cardiovascular procedures, debris from the aortic valve, ascending aorta, and other sources may embolize and cause cerebral infarction. The cerebral damage may not be clinically evident after cardiovascular procedures and can take months or years for symptoms to manifest, often presenting as devastating stroke, dementia, and cognitive decline.

Related Links:

Allium Medical
University of Leipzig



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Silver Member
Urine Test Strips
LabStrip U11 Plus
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: Researcher Nick Housley examines microscopic nanohydrogels, gel-like particles designed to carry drugs through the bloodstream (Photo courtesy of Georgia Tech)

Nanohydrogels Guide Medicine to Tumors Without Damaging Healthy Tissue

Many cancer treatments are effective at destroying tumors but can also damage healthy tissue, causing severe side effects for patients. This occurs because conventional chemotherapy drugs circulate throughout... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.